A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Andrea B. Apolo, Amir Mortazavi, Mark N. Stein, Sumanta K. Pal, Nicole N. Davarpanah, Howard L. Parnes, Yangmin M. Ning, Deneise C Francis, Lisa M Cordes, Paul Monk, Tiffany Lancaster, Rene Costello, Swati Nanda, Donald P. Bottaro, John Joseph Wright, Howard Streicher, Seth M. Steinberg, Marilise Berninger, Liza Lindenberg, William L. Dahut
Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, Rutgers Cancer Institute, City Of Hope National Medical Center, United States Food and Drug Administration, The Ohio State University
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2602480074